课题基金 / 基金详情

Targeting endothelial migration to prevent neovascularization

Targeting endothelial migration to prevent neovascularization
靶向内皮迁移以预防新血管形成
批准号:
9099868
负责人:
Anne Christine Eichmann
金额:
$41.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2019-04-30

项目摘要

项目成果

Anne Christine Eichmann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): The majority of severe vision loss in the US results from complications associated with retinal neovascularization in patients with ocular diseases, including diabetic retinopathy (DR) and Age- Related Macular Degeneration (AMD). These diseases are characterized by excessive angiogenesis, which promotes vascular leak leading to edema, hemorrhage and retinal detachment compromising vision. To date, the treatment of excessive angiogenesis relies largely on inhibition of a single factor, vascular endothelial growth factor (VEGF), with some therapeutic success. Clinical trials have shown that anti-VEGF treatment reduces angiogenesis in AMD and DR patients, indicating that anti-angiogenic treatment is a viable therapeutic option. However, treatments involve frequent intraocular injections, and a proportion of patients do not achieve vision improvement. Therefore, there is enormous therapeutic interest to develop treatments that enhance response to anti-VEGF agents and improve the lives of patients with ocular neovascular disease. We here identify the guidance molecule Slit2 as a requisite factor that promotes angiogenesis in addition to VEGF. Disruption of Slit2 function by temporally inducible deletion of the Slit2 gene, and combined deletion of its Robo1 and Robo2 receptors in ECs potently inhibits retinal neovascularization. These data lead us to test the hypothesis that blocking Slit2 signaling through Robo1 and 2 represents an alternative pathway to block excessive angiogenesis that may serve as a therapeutic target in conjunction with anti-VEGF treatment of AMD. Mechanistically, we will test the hypothesis that blocking of Slit2-Robo1/2 signaling improves efficacy of anti-VEGF treatment by selectively targeting EC migration and define the signaling pathways regulating this process. Our studies will provide the first comprehensive examination of Slit-Robo1/2-mediated angiogenesis in ocular neovascularization, determine its biological significance and define the molecular and cellular basis of Slit signaling through Robo1/2 signaling. Understanding these mechanisms will provide insight into signaling events required for polarized endothelial cell migration during neovascularization, which is a fundamental, yet poorly understood event in vascular biology. The ultimate goal of our proposal is to develop new therapies to prevent intraocular vascular disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of meningeal lymphatic vasculature in neuroimmune communication development
  • 批准号:
    10566682
  • 项目类别:
  • 资助金额:
    $52.41万
  • 财政年份:
    2023
  • 负责人:
    Anne Christine Eichmann
  • 依托单位:
Flow regulation of the Alk1/Eng pathway in vascular homeostasis and disease
  • 批准号:
    10718429
  • 项目类别:
  • 资助金额:
    $77.56万
  • 财政年份:
    2023
  • 负责人:
    Anne Christine Eichmann
  • 依托单位:
Dynamic control of vascular permeability in development and disease
  • 批准号:
    9977245
  • 项目类别:
  • 资助金额:
    $82.93万
  • 财政年份:
    2019
  • 负责人:
    Anne Christine Eichmann
  • 依托单位:
Dynamic control of vascular permeability in development and disease
  • 批准号:
    10207760
  • 项目类别:
  • 资助金额:
    $82.18万
  • 财政年份:
    2019
  • 负责人:
    Anne Christine Eichmann
  • 依托单位:
海外基金